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ABSTRACT 
Many Fic domain proteins, through catalyzing post translational modifications (PTM) of 
protein substrates, functionally contribute to bacterial pathogenesis and the regulation of bacterial 
growth. Furthermore, one form of Fic-mediated regulation is the Fic toxin-antitoxin system, 
whereby an antitoxin interacts with and inhibits the Fic toxin. This study sought to determine the 
functional importance of Mycobacterium tuberculosis Fic and its putative antitoxin protein, 
Rv3642c. Using M. tuberculosis H37Rv genetic deletion mutants, fic and Rv3642c were 
demonstrated to promote intracellular survival in human THP-1 macrophage-like cells. Unlike 
other Fic toxins, of Fic toxin-antitoxin systems, Fic did not inhibit bacterial growth in vitro in the 
absence of Rv3642c. Notably, Fic demonstrated in vitro AMPylation of a THP-1 cell extract 
protein as shown by immunodetection. Fic also exhibited auto-AMPylation activity. Interestingly, a 
mutation of the conserved histidine in the Fic domain motif, a residue previously shown to be 
critical for AMPylation, had no effect on Fic-mediated ATP hydrolysis or AMPylation activity. 
Rv3642c was demonstrated to form a complex with Fic when co-expressed in Escherichia coli, 
indicating a toxin-antitoxin interaction. Screening M. tuberculosis protein fractions and culture 
filtrate with α-Fic and α-Rv3642c rabbit antisera did not detect monomers of Fic or Rv3642c, thus 
the cellular localization of Fic and the Rv3642c-Fic complex remains unclear. The results of this 
study provide insight into the function of M. tuberculosis Fic, and suggest that Fic and Rv3642c 
are important for M. tuberculosis survival in the intracellular macrophage environment. 
Furthermore, these findings challenge the current dogma that Fic domain catalysis is dependent 
on the conserved histidine of the Fic motif. 
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CHAPTER 1 
INTRODUCTION 
1.1. Mycobacterium tuberculosis and Tuberculosis. 
Mycobacterium tuberculosis, the causative agent of tuberculosis, is a major threat to 
global public health. Tuberculosis is highly infectious through aerosol transmission and deadly. In 
2015, tuberculosis killed 1.5 million people and another 9.6 million people developed active 
tuberculosis.
1
 Active tuberculosis is contagious, and symptoms include fever, coughing, weight 
lose, weakness, and tissue damage.
2
 Intensive tuberculosis tissue damage is lethal. 
Nonetheless, the majority of people infected with M. tuberculosis control the infection without 
clearing it, leading to the onset of latent tuberculosis. Although latent tuberculosis is not 
contagious, there is a 5-10% chance that latent tuberculosis can develop into active tuberculosis 
during a person's lifetime.
3
 Worldwide, over 2 billion people are estimated to have latent 
tuberculosis.
1
 Furthermore, co-infection with HIV and M. tuberculosis is especially devastating, 
with tuberculosis being the leading cause of death for people with HIV/AIDS.
1
 Despite much effort 
to end the global threat from M. tuberculosis, there remains to be an effective solution for 
combating tuberculosis. 
Because current vaccines are not sufficient in preventing tuberculosis, a new efficacious 
tuberculosis vaccine is critically needed. Although the Bacillus Calmette-Guérin (BCG) vaccine 
has been extensively used throughout the world to prevent tuberculosis,
1
 this vaccine is 
inconsistent in providing tuberculosis immunity. For example, while BCG efficacy was about 80% 
in the UK, efficacy was 0% in South India.
4
 Furthermore, BCG causes disease in children infected 
with HIV and is therefore not ideal in regions endemic to tuberculosis and HIV.
5
 The shortcomings 
of the BCG vaccine have prompted the development of numerous tuberculosis vaccines, and 
although some have shown to be more effective than BCG, we still do not have a vaccine that 
completely prevents or eradicates M. tuberculosis infection (reviewed
6
). These vaccines fail to 
provide protective immunity, likely because they are not appropriately stimulating the immune 
system. In order to develop novel vaccines to combat tuberculosis, we need to further our 
understanding of M. tuberculosis pathogenesis and its interaction with the immune system. 
2 
 
In contrast to vaccines, current anti-tuberculosis drugs are effective against drug-
susceptible M. tuberculosis, but only if the drug regime is strictly followed. While antibiotic-
administration supervision programs, like the WHO Directly Observed Treatment, Short-course 
(DOTS),
7
 have considerably increased the tuberculosis cure rate, ensuring full completion of the 
drug regime remains a challenge because of the lengthy duration of therapy, drug toxicity, the 
need for combinational drug therapy, and access to drugs and adequate health care facilities in 
the developing world - where tuberculosis is endemic.
8
 Incomplete drug regime treatments have 
contributed to the emergence and rise of drug-resistant M. tuberculosis.
9
 Compared to the 
treatment of drug-susceptible tuberculosis, the drug regimes used to treat drug-resistant 
tuberculosis are often longer in duration, more toxic to the patient, and less effective at killing M. 
tuberculosis.
10
 Exasperating the problem, M. tuberculosis strains have recently emerged that are 
100% resistant to all current anti-tuberculosis drugs.
11
 Clearly there is need for anti-tuberculosis 
drug discovery. As with vaccines, the development of anti-tuberculosis drugs is a very active 
research area, although we have yet to discover drugs that adequately combat drug-resistant M. 
tuberculosis or drastically improve the drug regime for drug-susceptible M. tuberculosis 
(reviewed
12
). In order to develop novel drugs, we need to identify novel drug targets. 
Tuberculosis is a global health problem that necessitates more effective solutions. To 
develop novel tuberculosis solutions, a better mechanistic understanding of M. tuberculosis 
pathogenesis is necessary.  
3 
 
1.2 M. tuberculosis Infection of Macrophages in Tuberculosis Pathogenesis. 
The intracellular infection of macrophages by M. tuberculosis is important to tuberculosis 
pathogenesis, especially the early stages of tuberculosis (Fig. 1.1). M. tuberculosis is transmitted 
mostly through cough or expectoration from individuals suffering from active tuberculosis.
13
 When 
a healthy individual inhales aerosolized M. tuberculosis, the bacterium is deposited deep into the 
lung alveoli where it encounters resident alveolar macrophages.
14
 Alveolar macrophages, which 
normally function to clear bacterial invaders from the lungs, are instead parasitized by M. 
tuberculosis,
15
 and the infected alveolar macrophage then serves as a niche for M. tuberculosis 
replication.
16
 Although other cells of the immune system, such as monocytes, dendritic cells, and 
neutrophils, are also parasitized by M. tuberculosis,
17
 macrophages have been the most 
extensively studied cell type infected by M. tuberculosis (reviewed
18
). Nonetheless, the infection 
of alveolar macrophages stimulates recruitment of additional immune cells, including 
macrophages, to the site of infection (reviewed
19
). These cells form a granuloma, the hallmark of 
tuberculosis, which encases both the infected macrophages and extracellular M. tuberculosis 
(reviewed
20
). Once an adaptive immune response is mounted the granuloma macrophages are 
robustly activated,
21
 becoming resistant to intracellular M. tuberculosis.
22
 Despite the onset of 
adaptive immunity, it is theorized that M. tuberculosis persists within granuloma macrophages for 
years until the bacterium reactivates and causes latent tuberculosis (reviewed
23
). 
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Figure 1.1 Early Events of Tuberculosis Pathogenesis: M. tuberculosis Establishes 
Replication Niche within Infected Macrophages. (1) Infection with M. tuberculosis begins when 
an individual with active tuberculosis exhales the bacterium into the environment, mainly through 
cough and/or expectoration. (2) A healthy individual inhales aerosolized M. tuberculosis. (3) 
Inhaled M. tuberculosis is transported into the lung. (4) M. tuberculosis reaches an alveolus. (5) 
Once in the alveolus, M. tuberculosis infects resident alveolar macrophages (AM). Resident 
dendritic cells (DC) are also infected. Intracellular M. tuberculosis evades infected macrophage 
defenses and continues to replicate until an adaptive immune response is generated. Adapted 
from Hoagland et al., 2016,
12
 Tang et al., 2016,
6
 and Lerner et al., 2015.
24
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Macrophages are highly specialized professional phagocytes that clear bacterial invaders 
from tissue, working either alone or in concert with other cells of the immune system. Although 
macrophages use multiple processes to kill intracellular bacteria, M. tuberculosis has evolved to 
evade macrophage defenses and subvert the intracellular environment in favor of bacterial 
growth (Fig. 1.2). M. tuberculosis is well adapted to gain entry into macrophages by phagocytosis 
through the utilization of multiple phagocytosis receptors, with or without opsonization.
25
 Once 
phagocytized, M. tuberculosis prevents phagosome acidification, alters phagosome maturation, 
and prevents phagosome-lysosome fusion to avoid death.
26,27
 Lysosomes are home to hydrolytic 
enzymes that are highly bactericidal, even to M. tuberculosis. Intracellular M. tuberculosis may 
also inhibit macrophage production of microbicidal reactive oxygen species (ROS).
28
 From within 
the phagosome, M. tuberculosis replicates exponentially, which will result in macrophage lysis, 
release of the bacteria into the extracellular milieu, and further infection of macrophages that 
phagocytize the escaped bacteria. To prevent the macrophage from limiting intracellular bacterial 
growth through self-destruction, M. tuberculosis inhibits host apoptosis.
29
 Additionally, M. 
tuberculosis avoids immune surveillance by inhibiting host major histocompatibility complex 
(MHC) class II antigen processing and presentation.
30
 By preventing other immune cells from 
detecting intracellular M. tuberculosis and targeting infected cells for destruction, the bacterium 
further maximizes intracellular replication. Thus, because M. tuberculosis evades and subverts 
macrophage processes, the macrophage serves to provide a replication niche for M. tuberculosis. 
Despite known virulence strategies employed by M. tuberculosis to infect macrophages 
(reviewed
18
), the molecular mechanisms of these virulence strategies are largely not understood. 
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Figure 1.2 Schematic Showing Virulence Strategies Employed by Intracellular M. 
tuberculosis to Replicate within Macrophages. M. tuberculosis is well-adapted to thrive in the 
macrophage intracellular environment. M. tuberculosis gains entry into the macrophage through 
phagocytosis, utilizing a variety of phagocytic receptors. From within the phagosome, M. 
tuberculosis prevents phagosome-lysosome fusion, phagosome acidification and maturation, 
production of reactive oxygen species, apoptosis, and major histocompatibility complex (MHC) 
class II antigen presentation. Intracellular M. tuberculosis replicates exponentially, resulting in 
macrophage lysis and escape of the bacterium into the extracellular milieu. 
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1.3. Fic Domain Proteins. 
Fic (filamentation induced by cAMP) domain proteins are a family of enzymes that harbor 
a Fic domain which uses phosphate-containing compounds to catalyzes post translational 
modifications (PTM) of serine, threonine, and tyrosine residues (reviewed
31
). The first Fic domain 
protein was discovered in the 1980s, when a mutation in the gene encoding a Fic domain protein 
caused filamentous growth in E. coli in a cAMP-dependent manner.
32
 It wasn't until recently that 
the Fic domain was characterized to catalyze PTM.
33,34
 Many Fic domain proteins catalyze 
AMPylation, or adenylylation, which is the hydrolysis of ATP into AMP and subsequent transfer of 
AMP to a protein substrate. Similar to AMPylation, Fic domain proteins also can catalyze 
UMPylation, GMPylation, phosphocholination, and phosphorylation.
35,36,37
 Some Fic domain 
proteins can self-modify, i.e. auto-AMPylation,
35,38,39
 and moreover, some Fic domain proteins 
can catalyze multiple PTMs.
40
 Fic domain proteins are found in the three kingdoms of life, with the 
vast majority of Fic domain proteins found in bacteria (Fig. 1.3).
41
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Figure 1.3 Distribution of Fic Domain Proteins across All Three Kingdoms of Life. Over 
3,000 species harbor Fic domain proteins. The vast majority of Fic domain proteins are bacterial, 
most of which are gram-negative, and includes non-pathogenic and pathogenic species. The 
function of only a small fraction of these Fic domain proteins has been characterized. Adapted 
from Xiaobo et al 2015.
42
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Crystal structures of Fic domain proteins identify common features of Fic domains that 
provide a basis for predicting the specific PTM catalyzed by a given Fic domain. The Fic domains 
of AMPylators are comprised of six or more α-helices, a β-flap usually between helices α-2 and α-
3, and a core catalytic loop usually between either α-3 and α-4 or α-4 and α-5, altogether forming 
an ATP-binding pocket (Fig. 1.4A-B). The catalytic loop is highly conserved and identified by the 
signature Fic motif [HxFx(D/E)GNGRxxR].
43
 It is theorized that the histidine of the catalytic loop 
functions to deprotonate the hydroxyl group of the substrate threonine, tyrosine, or serine 
residue.
44,45
 In the AMPylation reaction, the deprotonated hydroxyl group performs a nucleophilic 
attack on the α-phosphate of ATP, cleaving it to produce AMP and pyrophosphate (Fig. 1.4C), 
subsequently resulting in the transfer of AMP to the hydroxyl group. Besides the histidine, the 
other conserved residues of the catalytic loop, as well as some conserved residues outside the 
catalytic loop, function to stabilize and position ATP for nucleophilic attack.
43,44
 Outside of the Fic 
domain catalytic loop, there is much variation and very little sequence similarity, even among Fic 
domains that catalyze AMPylation. Furthermore, Fic domains can have additional insertions 
throughout the domain, and many Fic domain proteins form dimers or higher order tetramers.
46,47
 
While efforts have been made to predict Fic domain PTM,
48
 Fic domain oligomer formation and 
recognition of protein substrate are poorly understood. 
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Figure 1.4 Fic Domain Structure and Catalysis. (A) Fic domain components. Fic domains 
typically have six or more core α-helices (pink). The catalytic loop (orange), composed of the 
conserved Fic motif [HxFx(D/E)GNGRxxR], is located on the loop region between two of the core 
Fic domain helices (shown here between α3 and α4). The β-flap (light blue) section serves to 
interact with the substrate. Additional insertions can be located at the N-terminus (green), C-
terminus (yellow), or within the Fic domain (dark blue). (B) Structural superposition of four Fic 
domain proteins shown as cartoons: IbpA Fic2 (Histophilus somni), BepA (Bartonella henselae), 
Doc (bacteriophage P1), and NmFic (Neisseria meningitidis). The components of the Fic domain 
are colored as in (A). (C) Proposed model for Fic domain catalysis with coordinated VopS amino 
acids (black) important for AMPylating, using ATP (red) as a cofactor, Cdc42 threonine (blue). 
The catalytic loop histidine (VopS His348) deprotonates the hydroxyl group of the Cdc42 threonine 
residue which activates the threonine for nucleophilic attack on the α-phosphate of ATP. A Mg
2+
 
ion stabilizes the transfer after ATP is cleaved. Adapted from Pino et al. 2014 (A-B)
49
 and Luong 
et al. 2010 (C).
45
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Although only a handful of bacterial Fic domain proteins have been characterized to date, 
several Fic domain proteins function in bacterial pathogenesis. For example, the Legionella 
pneumophila effector AnkX is delivered by a Type IV secretion system from the Legionella-
containing vacuole into the host cytoplasm.
35,50
 From the eukaryotic cell cytoplasm, AnkX 
phosphocholinates Rab GTPases, leading to subversion of host vesicular trafficking in support of 
bacterial intracellular growth. In another example, VopS, a Vibrio parahaemolyticus Type III 
secretion system effector, AMPylates Rho GTPases to collapse the actin cytoskeleton.
33
 VopS-
mediated AMPylation of Rho GTPases also leads to impairment of host antibacterial defenses, 
specifically NFκB signaling and ROS production, although the mechanism is unknown.
51
 
Histophilus somni IbpA is secreted by a two-partner secretion system and subsequently 
internalized by alveolar epithelial cells, where the two Fic domains of IbpA cause actin 
cytoskeleton collapse by AMPylating small GTPases.
34
 Additionally, the plant pathogen 
Xanthomonas campestris encodes the Type III secretion system effector AvrAC, a Fic domain 
protein that catalyzes UMPylation of kinases BIK1 and RIPK to impair host immune defenses.
36
 
Notably, the majority of Fic domain proteins that function in bacterial pathogenesis are from gram-
negative bacteria and are delivered into host cells via Type III or IV secretion systems. 
Many Fic domain proteins, of both pathogenic and nonpathogenic bacteria, are regulated 
by an inhibitory α-helix (αinh) identified by the motif (S/T)xxxE(G/N).
38
 The αinh is located near the 
N-terminus or C-terminus of the Fic domain protein or on a separate protein that interacts with the 
Fic domain protein.
38
 The glutamate of the αinh disrupts the cofactor, i.e. ATP, interaction with the 
Fic domain catalytic loop, preventing in-line nucleophilic attack and catalysis
52
 (Fig. 1.5). Deletion 
of the αinh, or mutation of its conserved glutamate (i.e. E to G), often relieves inhibition of Fic 
domain catalytic activity.
53,54
 However, the mechanism associated with αinh regulation of Fic 
domain catalysis is not fully understood, and the αinh does not always have an inhibitory role. For 
example, an E to G mutation of the αinh of CdFic, of the gram-positive Clostridium difficile, had no 
apparent affect on CdFic ATP binding or catalytic activity.
55
 When the Fic domain and αinh are 
located on separate proteins, the Fic domain protein and the αinh protein form a toxin-antitoxin 
system.
38
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Toxin-antitoxin systems are controlled complexes whereby toxin activity is inhibited by 
interaction with the antitoxin (reviewed
56
). Under certain conditions, the antitoxin is often 
degraded, thus releasing inhibition of the toxin. Toxin-antitoxin systems are commonly involved in 
bacterial regulatory processes, such as stress response, and are also involved in bacterial 
pathogenesis. Several Fic toxin-antitoxin systems have been characterized. In the VbhT-VbhA 
Fic toxin-antitoxin system (from Bartonella schoenbuchensis), the activity of VbhT is inhibited by 
VbhA (Fig. 1.5).
52,53
 Loss of function mutations of the VbhA αinh results in VbhT-mediated 
AMPylation of bacterial gyrase subunit B (GyrB) and topoisomerase IV homologues, causing 
reversible growth arrest and cell filamentation. However, the conditions and mechanism of 
deregulation are not understood. Toxin-antitoxin systems that function similarly to VbhT-VbhA 
have been characterized in Yersinia enterocolitica, Pseudomonas aeruginosa, and Pseudomonas 
fluorescens.
53,54
 Furthermore, in the Doc-PhD Fic toxin-antitoxin system, the PhD antitoxin, which 
lacks an αinh motif, inhibits Doc activity by seemingly obstructing interaction between ATP and the 
Fic domain catalytic loop of Doc.
37
 Specific stress conditions cause PhD to degrade, resulting in 
Doc phosphorylation and inactivation of bacterial elongation factor Tu (EF-Tu), thereby impairing 
bacterial translation.
37
 Notably, Doc-Phd has been shown to contribute to formation of Salmonella 
enterica subsp. enterica serovar Typhimurium persisters after uptake by macrophages.
57
 Fic toxin 
and antitoxin genes are generally adjacent to each other on the bacterial chromosome and often 
form an operon.
38
 While the localization of Fic toxin-antitoxin systems has not been extensively 
studied, VbhT is secreted by a Type IV secretion system.
38
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Figure 1.5 In the Fic Toxin-Antitoxin System, the Antitoxin Tightly Binds the Fic Toxin to 
Inhibit Fic Catalytic Activity with the Inhibitory α-helix (αinh). When the antitoxin is complexed 
with the Fic toxin (FIC), the glutamate of the antitoxin αinh is positioned at the ATP-binding site in 
a way that prevents ATP from forming hydrogen bounds with all of the Fic domain residues 
necessary for nucleophilic attack of the ATP. Although the αinh does not prevent ATP from binding 
the Fic domain, the αinh forces the bound ATP into a catalytically inactive position. When the Fic 
domain protein (FIC) is relieved of αinh-mediated inhibition, ATP binds in a catalytically active 
position, and the Fic domain catalytic loop is able to catalyze the reaction. Adapted from Engel et 
al. 2012.
38
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1.4. M. tuberculosis Fic and Rv3642c. 
M. tuberculosis Fic harbors the conserved Fic motif, and according to a 2012 study by 
Mishra et al.,
58
 Fic is predicted to have Fic domain structural homology to AMPylators. The 
authors showed that Fic has 31% sequence identity and 47% sequence similarity with the known 
AMPylator, VbhT. Like the Fic domain of VbhT, M. tuberculosis Fic contains seven α-helices, with 
a β-flap between helices α-2 and α-3, and the conserved Fic motif between helices α-4 and α-5 
(Fig. 1.6A-B). The entire M. tuberculosis Fic protein consists of a single Fic domain. 
Superimposition of the predicted Fic ATP-binding pocket with the IbpA Fic2 ATP-binding pocket 
strongly suggests that Fic accepts ATP into the same orientation as IbpA Fic2, which implies Fic 
catalyzes AMPylation (Fig. 1.6C). Furthermore, Fic has a canonical Fic domain and a conserved 
arginine residue (Arg 87), located on the loop region between helices α-2 and α-3, that is 
predicted to stabilize ATP in the ATP-binding pocket (Fig. 1.6D). In contrast, non-AMPylating Fic 
domain proteins, like Doc and AnkX, have a non-canonical Fic motif, lack the conserved arginine 
between their respective Fic domain helices α-2 and α-3, and accept their cofactors in an 
opposite orientation compared to AMPylators.
37,44
 Mishra et al.
58
 further demonstrated that Fic 
hydrolyzes ATP into AMP and that ATP hydrolysis is dependent on the conserved Fic residues: 
R87, H144, E148, and N150. 
Immediately upstream of the fic gene (fic encodes Fic) on the M. tuberculosis 
chromosome is Rv3642c which encodes the hypothetical protein Rv3642c. Sequence analysis of 
Rv3642c reveals a non-canonical αinh motif (N24TELEG), which differs slightly from the canonical 
αinh motif (S/T)xxxE(G/N). Like most genes that encode Fic toxin-antitoxin systems, fic and 
Rv3642c are adjacent on the chromosome, separated by 10 bp, and appear to be part of an 
operon. Altogether, this evidence suggests Fic and Rv3642c form a toxin-antitoxin system. 
Although little is known about Fic and Rv3642c, there is some evidence that they are 
important for tuberculosis pathogenesis. Notably, fic is upregulated after 24 and 48 h post M. 
tuberculosis infection of macrophages,
59
 and fic is upregulated in blood from both HIV-negative 
and HIV-positive individuals infected with M. tuberculosis.
60
 Furthermore, Fic has been detected 
in the M. tuberculosis culture filtrate, suggesting that the protein is secreted.
61
 Additional evidence 
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that supports Fic secretion is the discovery that Fic is an immuno-dominant antigen for CD8
+
 T-
cells.
62
 These cytotoxic T-cells recognize antigens presented by the MHC Class I pathway of 
which secreted proteins are typically processed.
63
 Rv3642c was also upregulated during 
macrophage infection by M. tuberculosis.
59
 Unlike Fic, Rv3642c has not been detected in any 
proteomic studies (to the best of author's knowledge). 
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Figure 1.6 Structural Comparisons between the Predicted Structure of M. tuberculosis Fic 
and the Crystal Structures of VbhT (from B. schoenbuchensis) and IbpA Fic1 (from 
Histophilus somni). (A) Superimposed Fic (red) and VbhT (purple) structures represented as 
ribbon diagrams, showing the Fic motif [HxFx(E/D)GNGRxxR] (green), β-flap, and seven α-
helices. (B) Cartoon schematic representing the structural topology of Fic from (A). Loop regions 
are represented as thick black lines, the Fic motif is represented as a red line, and the seven α-
helices are represented as cylinders. (C) Superimposed positioning of the predicted Fic ATP 
binding-pocket (blue) with the IbpA Fic2 ATP-binding pocket (red), shown as stick 
representations. Bound AMP is shown as a CPK model colored by the type of atom. Key amino 
acid residues of the Fic motif are labeled. (D) Multiple alignment of Fic, VbhT, IbpA Fic2, Doc 
(from bacteriophage P1), and AnkX (from Legionella pneumophila), showing conserved residues 
of the Fic motif (red) and the conserved arginine located between helices α-2 and α-3. Non-
canonical Fic motif residues are blue. (A) and (C) are adapted from Mishra et al. 2012.
58
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1.5 Specific Aims and Summary of Thesis. 
The objective of this thesis was to characterize the function of M. tuberculosis Fic and Rv3642c 
and to determine their role(s), if any, in tuberculosis pathogenesis. We hypothesized that Fic is an 
AMPylator and that Fic AMPylation activity is important during M. tuberculosis infection of 
macrophages. We also hypothesized that Fic and Rv3642c form a toxin-antitoxin system. Four 
specific aims were addressed in this thesis: 
 
1) Generate M. tuberculosis fic, Rv3642c, and Rv3642c-fic mutants and complementation 
strains, and use those strains to investigate M. tuberculosis in vitro growth and 
intracellular survival during macrophage infection. 
2) Determine if Fic has in vitro AMPylation activity and if Fic AMPylates human macrophage 
and/or bacterial protein targets. 
3) Determine if there is protein-protein interaction between Fic and Rv3642c. 
4) Generate M. tuberculosis Fic and Rv3642c polyclonal antisera and use the antisera to 
investigate Fic and Rv3642c cellular localization. 
 
The results of this study demonstrate that fic and Rv3642c promote intracellular survival 
in the human THP-1 macrophage-like cells. Fic is also demonstrated to be an AMPylator, with 
both self (auto-AMPylation) and THP-1 protein substrate targets. Furthermore, Fic and Rv3642c 
were shown to form a robust complex, suggesting toxin-antitoxin interactions. However, our 
results indicate that Fic is not toxic to M. tuberculosis. Attempts to determine Fic and Rv3642c 
cellular localization were inconclusive. Altogether, this study provides evidence suggesting Fic 
AMPylation is important to M. tuberculosis infection of macrophages, and therefore tuberculosis 
pathogenesis. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Bacterial Strains and Growth Conditions. 
Escherichia coli strains JM109, HB101, GM2198, and BL21(DE3) were grown in either 
TYM broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl, 0.2% maltose), 2X YT broth (1.6% 
tryptone, 1% yeast extract, 0.5% NaCl, pH 7.0), Luria-Bertani (LB) broth, or on LB agar at 37°C. 
E. coli strains harboring plasmids were grown with antibiotics at the following concentrations: 
apramycin (Am) – 35 µg/ml, kanamycin (Km) – 50 µg/ml, ampicillin (Ap) – 100 µg/ml, and 
hygromycin B (Hyg) – 150 µg/ml. M. tuberculosis H37Rv (ATCC 27294) and mutants (described 
in 2.2) were grown at 37°C in Middlebrook 7H9 broth (Difco, Franklin Lakes, NJ) supplemented 
with 0.2% glycerol, 10% ADS (0.5% bovine serum albumin, 0.2% glucose, 140 mM NaCl), and 
0.05% Tween 80 (TW) (7H9/ADS/TW) or on Middlebrook 7H10 agar (Difco, Franklin Lakes, NJ) 
supplemented with 0.5% glycerol and 10% ADS (7H10/ADS). Mycobacterium smegmatis mc
2
155 
(ATCC 700084) was grown at 37°C either in 7H9/ADS/TW or on LB agar. 
 
 
2.2 Generation of M. tuberculosis Knockout and Complementation Mutants. 
M. tuberculosis allelic exchange mutants were generated using temperature-sensitive 
recombinant mycobacteriophages.
64
 In short, the flanking regions of fic and Rv3642c were PCR 
amplified from H37Rv genomic DNA and cloned on either side of the res-hyg
R
-res cassette (hyg
R
) 
of pYUB854.
64
 The fic upstream and downstream flanking regions were cloned into pYUB854 to 
generate pSH842 (Δfic::hyg
R
). The Rv3642c upstream and downstream flanking regions were 
cloned into pYUB854 to generate pSH847 (ΔRv3642c::hyg
R
). The Rv3642c-fic upstream and 
downstream flanking regions were cloned into pYUB854 to generate pSH852 (ΔRv3642c-
fic::hyg
R
). PacI-digested, concatemerized phAE87 DNA
64
 was ligated to PacI-digested plasmids 
pSH842, pSH847, and pSH852, packaged into λ phage heads (GigaPack III; Strategene, La 
Jolla, CA), and used to infect E. coli HB101 to generate phSH842, phSH847, and phSH852 
phasmids, respectively. After electroporation of purified phasmids into M. smegmatis mc
2
155, 
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mycobacteriophage plaques were generated at 30°C. Confirmed temperature-sensitive 
recombinant mycobacteriophages were used to generate high titer phage lysates and infect M. 
tuberculosis H37Rv. M. tuberculosis colonies resistant to Hyg (50 µg/mL) were grown, and 
genomic DNA was analyzed by Southern blot (Fig. 3.1). Confirmed allelic exchange ΔRv3642c-
fic::hyg
R
, ΔRv3642c::hyg
R
, and Δfic::hyg
R
 mutants were designated M. tuberculosis STS80, 
STS81, and STS82, respectively. 
For genetic complementation with Rv3642c-fic with its native promoter, a PCR product, 
encompassing the full-length Rv3642c and fic open reading frames (ORF) with 414 bp of the 
upstream promoter region and 242 bp downstream of the fic stop codon, was cloned into pSH492 
(pMV306::aacC41
65
), to generate pSH874 (PWT-Rv3642c-fic). For genetic complementation with 
Rv3642c with its native promoter, the Rv3642c ORF with 414 bp of the upstream promoter region 
and 282 bp downstream of the Rv3642c stop codon was cloned into pSH492 to generate pSH844 
(PWT-Rv3642c).  For genetic complementation with fic with its native promoter but without 
incorporating Rv3642c, we generated an internal deletion of the first 147 bp of Rv3642c using 
overlap extension PCR.
66
 The resulting DNA, harboring 414 bp of the Rv3642c upstream 
promoter region, 48 bp of the 3’-end of Rv3642c, the 10 bp region between the Rv3642c and fic 
ORFs, the fic ORF, and 242 bp downstream of the fic stop codon, was cloned into pSH492 to 
generate pSH872 (PWT-fic). DNA sequencing confirmed all recombinant plasmids. The pSH872 
(PWT-fic), pSH844 (PWT-Rv3642c), and pSH874 (PWT-Rv3642c-fic) integrative plasmids were 
electroporated into the respective mutant strains (STS80, STS81, and STS82, respectively), and 
Am-resistant M. tuberculosis colonies validated by Southern analysis (Fig. 3.1) were designated 
STS83 (ΔRv3642c-fic::PWT-fic), STS86 (ΔRv3642c::PWT-Rv3642c), and STS91 (Δfic::PWT-
Rv3642c-fic). 
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2.3 THP-1 Cell Infection Assays. 
The human monocyte-like cell line THP-1 (ATCC TIB-202) was maintained in RPMI 1640 
supplemented with 10% heat-inactivated FBS and incubated at 37°C with 5% CO2. For infection 
experiments, THP-1 cells were differentiated to macrophages by treatment with 20 ng/mL phorbol 
12-myristate 13-acetate (PMA; Thermo Fisher Scientific, Waltham, MA) 48 h prior to infection. 
Differentiated THP-1 cells were seeded in 96-well tissue culture plates at a density of 1 x 10
5
 
cells/well. M. tuberculosis strains were grown to mid-logarithmic phase (OD600 of 0.5 to 0.6), 
harvested by centrifugation, and suspended in 7H9/ADS/TW supplemented with 10% glycerol. 
Cell suspensions were then passaged through a 5-µm filter to generate M. tuberculosis single cell 
suspensions and stored at -80°C as 1 mL aliquots. Single-cell suspensions were thawed, diluted 
in tissue culture medium, and CFU/mL was enumerated by generating serial dilutions of thawed 
cells and plating onto 7H10/ADS agar. Prior to infection, THP-1 monolayers were washed twice 
with PBS and infected with thawed M. tuberculosis single cell suspensions at a calculated MOI of 
1. After incubating 4 h to allow for phagocytosis, the supernatant was aspirated, and the THP-1 
cell monolayers were washed twice with PBS to remove extracellular bacteria. On days 1, 3, 5, 
and 7 post-infection, extracellular bacteria were collected by pooling the culture supernatant and 
two PBS washes and quantified by plating on 7H10/ADS agar. Infected macrophages were lysed 
with 0.05% SDS for 5 min. After pooling the lysate with two 0.5% SDS washes and performing 
serial dilutions, intracellular CFU were determined by plating on 7H10/ADS agar. All 7H10/ADS 
agar plates were incubated for 2-3 weeks at 37°C prior to CFU quantitation. 
 
 
2.4 Plasmid Manipulations for Protein Expression. 
For cloning into pMCSG19 (DNASU, Tempe, AZ), fic was PCR amplified from H37Rv 
genomic DNA and treated with T4 DNA polymerase in the presence of dCTP to create ligation 
independent cloning (LIC) overhangs. Similarly, SspI-digested pMCSG19 was treated with T4 
DNA polymerase in the presence of dGTP to create LIC overhangs. The LIC-overhang fic PCR 
product and the LIC-overhang vector were combined to generate pSH900 and transformed into 
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E. coli JM109. For cloning fic H144A (H/A) into pMCSG19, fic H144A was PCR amplified from 
pcDNA6.2/N-EmGFP-DEST::fic H/A (plasmid provided by our collaborators) and cloned into 
pMCSG19 as described above, thus generating pSH901. For cloning into pTZ842,
67
 fic, Rv3642c, 
and Rv3642c-fic, were PCR amplified from H37Rv genomic DNA, directionally cloned into 
pTZ842 to generate pSH854, pSH855, and pSH856, respectively, and transformed into E. coli 
JM109. Similarly, fic H/A was PCR amplified from pcDNA6.2/N-EmGFP-DEST::fic H/A, 
directionally cloned into pTZ842 to generate pSH861, and transformed into E. coli JM109. 
Transformants were selected on LB plates with either Ap (pMCSG19) (100 µg/mL) or Km 
(pTZ842) (50 µg/mL). Recombinant plasmids were sequenced to confirm the absence of PCR-
induced mutations and transformed into E. coli BL21(DE3). 
 
 
2.5 Protein Expression and Purification. 
GST-Δ30 VopS, GST-IbpA Fic1, and GST-Rac1 G12V were expressed and purified as 
previously described.
68
 For generation of MBP (maltose-binding protein)-6xHis-Fic (MBP-Fic), 
MBP-6xHis-Fic H/A (MBP-Fic H/A), 3xFLAG-Fic-6xHis (FLAG-Fic), and 3xFLAG-Fic H/A-6xHis 
(FLAG-Fic H/A) for enzymatic assays, E. coli BL21(DE3) cells, transformed with pSH900, 
pSH901, pSH854, and pSH857, respectively, were induced with 0.01 mM IPTG for 18 h at room 
temperature. E. coli cells were homogenized by bead-beating (FastPrep-24
TM
, MP Biomedicals, 
Solon, OH) in native lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 50 mM NaH2PO4), and 
proteins were captured using Ni-NTA resin (Invitrogen, Carlsbad, CA) or glutathione-agarose 
(Sigma, St. Louis, MO). For generation of MBP-Fic and FLAG-Rv3642c-His to be used as 
antigens for immunizing rabbits, E. coli B21(DE3) cells, transformed with pSH900 and pSH855, 
respectively, were induced with IPTG for 4 h at 37°C. E. coli cells were homogenized as 
described above, but in urea lysis buffer (8 M urea, 10 mM Tris-Cl, pH 8.0, 100 mM NaCl, 50 mM 
NaH2PO4), and then purified as described above. Proteins were subjected to buffer exchange in 
20 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, and 1 mM DTT with Amicon
TM
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concentrators (EMB Millipore, Billerica, MA) or by dialysis, flash frozen, and stored at -70°C. 
Protein concentrations were determined by the Bradford assay. 
 
 
2.6 In Vitro ATP Hydrolysis Assay. 
ATP hydrolysis activity of 400ng or 800ng purified MBP, VopS, MBP-Fic, MBP-Fic H/A, 
FLAG-Fic, and FLAG-Fic H/A were quantified using a luciferase-based ATP determination kit 
(Molecular probes) according to the manufacturer's protocol. In short, the proteins were incubated 
in reaction buffer (5 mM Hepes, pH 7.4, 1.25 mM MgCl2, 25 mM NaCl, and 0.25 mM DTT) with 1 
mM ATP at 30°C for 1 h and 16 h. The ATP determination kit reaction solution, containing 
luciferase, was added to the protein samples, and luminescence, which correlates to the amount 
of ATP, was quantified with a luminometer (PerkinElmer, Waltham, MA). 
 
 
2.7 In Vitro AMPylation Assays. 
For immunodetection of AMPylation, in vitro AMPylation reactions with purified protein 
substrate (200 ng GST-Rac1 G12V) or cellular protein substrates (15 µg THP-1 WCL, 1.3 µg 
H37Rv WCL) and AMPylator enzymes (3 µg MBP-Fic and MBP-Fic H144A, 33 ng GST-Δ30 
VopS, and 24 ng GST-IbpA Fic1) or 3 µg MBP, were mixed with 10 mM ATP in AMPylation buffer 
(20 mM Hepes pH 7.4, 5 mM MgCl2, 100 mM NaCl, and 1 mM DTT), and incubated at 37°C for 1 
h. Samples were mixed with SDS-PAGE loading dye, boiled, and separated via SDS-PAGE. For 
western analyses, proteins were transferred to PVDF membranes and probed with α-AMPylated 
threonine or α-AMPylated tyrosine polyclonal antibodies (EMB Millipore, Billerica, MA), or α-β-
actin polyclonal antibodies (Cell Signaling Technology, Davers, MA), with HRP-conjugated anti-
rabbit IgG as a secondary antibody (ThermoFisher Scientific, Waltham, MA). Immunoblots were 
developed using the ECL detection kit (GE Healthcare, Chicago, IL). 
For click chemistry detection of AMPylation, in vitro AMPylation reactions were performed 
similarly as AMPylation immunodetection assays with the following exceptions. Protein samples 
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were mixed with 10 mM N
6
pATP (Jena Bioscience, Jena, Germany) in AMPylation buffer (5 mM 
Hepes, pH 7.4, 1.25 mM MgCl2, 25 mM NaCl, and 0.25 mM DTT) and incubated at 30°C for 1 h. 
Protein samples were further incubated in azide-rhodamine (az-rho) solution (0.1 mM 
sulforhodamine 101 azide (Click Chemistry Tools, Scottsdale, AZ), 1.6% SDS, 60 mM NaCl, 20 
mM triethanolamine, pH 7.5, 1 mM tris(2-carboxyethyl)phosphine, 0.1 mM tris[(1-benzyl-1H-1,2,3-
triazol-4-ul)methyl]amine, and 1 mM CuSO4) for 1 h at room temperature. Az-rho reactions were 
stopped by addition of SDS-PAGE loading dye, proteins were separated by SDS-PAGE, and in-
gel fluorescence was scanned at 523 nm with a Typhoon
TM
 Imaging System (Amersham 
Bioscience, Buckinghamshire, United Kingdom). 
For autoradiography AMPylation detection, in vitro AMPylation reactions were performed 
similarly as AMPylation immunodetection assays with the following exceptions. ATP was replaced 
with 10 µCi α-
32
P-ATP (3,000 Ci/mmol), and reactions were incubated in either AMPylation buffer 
(20 mM Hepes pH 7.4, 5 mM MgCl2, 100 mM NaCl, and 1 mM DTT) for 1 h at 37°C or in 
AMPylation buffer (5 mM Hepes, pH 7.4, 1.25 mM MgCl2, 25 mM NaCl, and 0.25 mM DTT) for 1 
h at 30°C. Proteins were separated by SDS-PAGE and in-gel autoradiography was visualized 
with a phosphorimager (Amersham Bioscience, Buckinghamshire, United Kingdom). 
For generation of THP-1 cell whole cell lysate (WCL), the human monocyte-like cell line 
THP-1 was maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS and 
incubated at 37°C with 5% CO2. After THP-1 cells were differentiated into macrophages by 
treatment with 20ng/mL phorbol 12-myristate 13-acetate (PMA; Thermo Fisher Scientific, 
Waltham, MA) for 24 h, whole cell lysates (WCL) were prepared. For generation of HeLa cell 
WCL, HeLa cells were maintained in DMEM supplemented with 10% FBS and incubated at 37°C 
with 5% CO2. HeLa cells and differentiated THP-1 cells were washed twice with PBS and 
subsequently incubated with lysis buffer [20 mM Tris-Cl pH 8.0, 50 mM NaH2PO4, 150 mM NaCl, 
0.5% Triton X-100, 1 mM EDTA, protease inhibitor cocktail (Roche, Basel, Switzerland)] for 30 
min at 4°C. For generation of M. tuberculosis H37Rv WCL, H37Rv cells were grown to 
logarithmic phase (OD600 between 0.6 and 1.0), washed twice with PBS, and homogenized by 
bead-beating with a FastPrep-24
TM
 (MP Biomedicals, Santa Ana, CA) in lysis buffer (PBS, 1 mM 
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DTT, protease inhibitor cocktail (Roche, Basel, Switzerland)). WCL samples were clarified by 
centrifuging at 21,000 x g for 30 min at 4°C. Protein concentration was determined via the BCA 
method (ThermoScientific Pierce, Rockford, IL). WCL samples were flash frozen and stored at -
70°C. 
 
 
2.8 Co-Expression and Complex Detection Assay. 
For 3xFLAG-Fic-6xHis and 3xFLAG-Rv3642c-6xHis expression and Fic-6xHis and 
3xFLAG-Rv3642c co-expression, E. coli BL21(DE3) cells transformed with pSH854, pSH855, 
pSH856, respectively, were induced with 0.1 mM IPTG for 4 h at 37°C. E. coli cells were then 
mixed with SDS-PAGE loading dye and boiled for 10 min. The resulting lysate was separated by 
SDS-PAGE, transferred to PVDF membrane ,and analyzed by immunodetection with α-FLAG 
(Sigma, St. Louis, MO) and α-His (ThermoFisher Scientific, Waltham, MA) monoclonal antibodies 
with HRP-conjugated α-mouse IgG as secondary antibody (ThermoFisher Scientific, Waltham, 
MA). 
 
 
2.9 Generation of Rabbit Antisera and Cellular Localization Studies. 
α-MBP-Fic and α-3xFLAG-Rv3642c-6xHis (α-FLAG-Rv3642c) polyclonal antisera were 
raised in rabbits as previously described,
69
 using the adjuvant Alum (InvivoGen, San Diego, CA). 
Briefly, rabbits were immunized with 50:50 mixtures of the adjuvant:antigen with either purified 25 
µg MBP-Fic or 10 µg 3xFLAG-Rv3642c-6xHis. Extracted antisera was clarified by centrifugation 
and stored at -20°C in 50% glycerol. 
To prepare WCL and culture filtrate proteins (CFP) from M. tuberculosis H37Rv wild-type 
and mutants (STS80, STS81, STS82, STS83, STS86, and STS91), M. tuberculosis cells were 
grown to late-logarithmic phase of growth. The culture supernatant and cellular pellet were 
separated via centrifugation (5,000 x g, 10 min, 4°C) and both were frozen at -80°C. The cellular 
pellet was resuspended in lysis buffer (8 M urea, 10 mM Tris-Cl, pH 8.0, 100 mM NaH2PO4), 
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incubated at room temperature for 1 h, homogenized by bead-beating with 0.1 mM zirconium 
beads with a FastPrep-24
TM
 (MP Biomedicals, Santa Ana, CA), and clarified by centrifugation. 
The culture supernatant was concentrated and buffer exchanged into storage buffer (20 mM 
Hepes, pH 7.4, 150 mM NaCl, 10% glycerol) with an Amicon concentrator (5 kDa molecular 
weight cut off) (EMB Millipore, Billerica, MA). WCL and CFP samples were flash frozen and 
stored at -70°C. Protein concentration was determined via the BCA method. H37Rv cytosol (NR-
14834), culture filtrate (NR-14825), cell wall (NR-14828), cell membrane (NR-14831), and Triton 
X-114 solubilized (NR-14841) protein fractions were ordered from BEI Resources (Manassas, 
VA). 
BEI Resources M. tuberculosis H37Rv protein fractions (5 µg) and WCL (7.5 µg) and 
CFP (15 µg) from M. tuberculosis H37Rv wild-type and mutant strains were separated by SDS-
PAGE, transferred to PVDF membrane, and probed with antisera (1:400) with HRP-conjugated α-
rabbit IgG as a secondary antibody (ThermoFisher Scientific, Waltham, MA). Immunoblots were 
developed with the ECL detection kit (GE Healthcare, Chicago, IL). Purified MBP-Fic (25 ng) and 
FLAG-Fic (100 ng) were used as positive controls in the immunoblots. 
 
 
2.10 Statistical Analyses. 
M. tuberculosis in vitro growth and intracellular survival data were analyzed by two-way 
ANOVA and Dunnett’s multiple comparisons to assess statistical significance. ATP hydrolysis 
data were analyzed by one-way ANOVA and Dunnett's test to assess statistical significance. 
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, San Diego, 
CA), and multiplicity-adjusted p values of < 0.05 were considered statistically significant.  
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CHAPTER 3 
RESULTS 
3.1 The Rv3642c-fic Locus is Not Essential for M. tuberculosis Viability. 
M. tuberculosis fic, Rv3642c, and Rv3642c-fic deletion mutants were constructed for use 
in experiments aimed at determining the functional role of these genes during M. tuberculosis in 
vitro growth (Results 3.2) and intracellular survival (Results 3.3). Using thermosensitive 
recombinant mycobacteriophages,
64
 M. tuberculosis H37Rv::Δfic::hyg
R
, H37Rv::ΔRv3642c::hyg
R
, 
and H37Rv::ΔRv3642c-fic::hyg
R
 deletion mutants were generated (Fig. 3.1). Previously, it was 
shown that neither fic nor Rv3642c are essential for H37Rv growth in vitro using transposon 
insertion mutants,
70,71
 which the results here corroborate. Moreover, these results demonstrate 
that the Rv3642c-fic locus is not essential for M. tuberculosis H37Rv viability in vitro. 
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Figure 3.1 Southern Blot Analysis of M. tuberculosis ΔRv3642c-fic, ΔRv3642c, and Δfic 
Deletion Mutants and ΔRv3642c-fic::PWT-fic, ΔRv3642c::PWT-Rv3642c, and Δfic::PWT-
Rv3642c-fic Complementation Strains. (A) Schematic diagram of the Rv3642c-fic and attBL5 
loci on the M. tuberculosis chromosome for deletion mutants and complementation strains. Also 
shown are PstI restriction digest sites, PstI-digested chromosomal DNA fragments, adjacent 
ORFs, the hyg
R
 gene (white) position after allelic exchange, and the positions of the hybridization 
probes (boxes): fic, Rv3642c, aacC41, and hyg
R
. Lane numbers correspond with the designated 
lanes of the Southern blot hybridizations in panel (B). (B) Southern blot hybridizations of M. 
tuberculosis PstI-digested genomic DNA for wild-type H37Rv (lane 1), ΔRv3642c-fic (lane 2), 
ΔRv3642c (lane 3), Δfic (lane 4), ΔRv3642c-fic::PWT-fic (lane 5), ΔRv3642c::PWT-Rv3642c (lane 
6), and Δfic::PWT-Rv3642c-fic (lane 7). pSH874 (lane 8) is a positive control containing fic, 
Rv3642c, and aacC41. pYUB854 (lane 9) is a positive control containing hyg
R
. Hybridization 
probes (fic, Rv3642c, aacC41, and hyg
R
) are designated for each Southern blot. 
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3.2 fic Does Not Inhibit M. tuberculosis In Vitro Growth. 
Fic toxin-antitoxin systems have been shown to function in regulating bacterial growth.
53
 
In these systems, expression of the Fic toxin in the absence of the antitoxin inhibits bacterial 
growth. To determine if the Rv3642c-fic locus has a functional role in regulating M. tuberculosis 
growth, the H37Rv deletion mutants Δfic, ΔRv3642c, and ΔRv3642c-fic and the complementation 
strains ΔRv3642c-fic::PWT-fic, ΔRv3642c::PWT-Rv3642c, and Δfic::PWT-Rv3642c-fic (Fig. 3.1) were 
cultured in M7H9 broth and growth was monitored by optical density and CFU quantification. The 
Δfic, ΔRv3642c, and ΔRv3642c-fic mutants exhibited enhanced growth that was 6-fold, 10-fold, 
and 6-fold greater, respectively, than wild-type H37Rv during late-log phase growth (day 7) (Fig. 
3.2A, C-E). None of the complementation strains restored growth to wild-type H37Rv levels, and 
instead all of the complementation strains exhibited growth similar to the deletion mutants (Fig. 
3.2B-E). Notably, the ΔRv3642c-fic::PWT-fic complementation strain showed improved in vitro 
growth (Fig. 3.2C), suggesting that fic, in the absence of Rv3642c, doesn’t inhibit in vitro growth. 
To discern whether the failure of the complementation strains to restore growth to wild-
type H37Rv levels was due to lower expression of Fic and/or Rv3642c relative to wild-type 
H37Rv, Fic and Rv3642c protein expression was assessed. WCLs and CFPs of the M. 
tuberculosis deletion mutants, complementation strains, and wild-type H37Rv were prepared from 
cultures grown to late-log phase in M7H9 broth and probed with rabbit α-Fic and α-Rv3642c 
polyclonal antisera. However, while recombinant MBP-Fic and FLAG-Rv3642c-His (used as 
positive controls) were detected by the antisera, neither Fic nor Rv3642c were detected in any of 
the strains, including wild-type (data not shown). These results suggest that Fic and Rv3642c are 
either expressed at extremely low levels, or not expressed at all, during M. tuberculosis late-log 
phase growth in M7H9 broth. 
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Figure 3.2 In Vitro Growth and Intracellular Survival of M. tuberculosis Δfic, ΔRv3642c, 
ΔRv3642c-fic Deletion Mutants and the Δfic::PWT-Rv3642c-fic, ΔRv3642c::PWT-Rv3642c, 
and ΔRv3642c-fic::PWT-fic Complementation Strains, Compared to Wild-Type H37Rv. (A-E) 
M. tuberculosis in vitro growth in M7H9 broth. Growth, presented as fold change compared to day 
0, was determined by quantifying CFU over a 15-day time course. (F-J) Human THP-1 
macrophage-like cells were infected with M. tuberculosis wild-type H37Rv, Δfic, ΔRv3642c, 
ΔRv3642c-fic, Δfic::PWT-Rv3642c-fic, ΔRv3642c::PWT-Rv3642c, and ΔRv3642c-fic::PWT-fic at an 
MOI of 1. Intracellular bacteria were quantified on days 0, 1, 3, 5, and 7. Intracellular survival is 
presented as fold change compared to day 0. Results are the means and standard error of the 
mean collected from duplicate wells from three independent experiments. Asterisks indicate 
significant differences between the deletion mutant strains (Δfic, ΔRv3642c, ΔRv3642c-fic) and 
wild-type H37Rv; *, p < 0.05; **, p < 0.01; ****, p < 0.0001; ANOVA, Dunnett's multiple 
comparisons.  
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3.3 The Rv3642c-fic Locus Promotes M. tuberculosis Intracellular Survival during Infection 
of THP-1 cells. 
M. tuberculosis is well adapted for intracellular survival in macrophages. To assess 
whether the Rv3642c-fic locus contributes to M. tuberculosis intracellular survival, human THP-1 
macrophage-like cells were infected with the Δfic, ΔRv3642c, ΔRv3642c-fic, Δfic::PWT-Rv3642c-
fic, ΔRv3642c::PWT-Rv3642c, and ΔRv3642c-fic::PWT-fic mutant strains and wild-type H37Rv, and 
intracellular bacteria were quantified at 0, 1, 3, 5, and 7 days post infection (p.i.). All three deletion 
mutants exhibited decreased survival characteristics with the Δfic, ΔRv3642c, and ΔRv3642c-fic 
mutants displaying significant 6-fold, 8-fold, and 9-fold reductions, respectively, of intracellular 
bacteria compared to wild-type H37Rv on day 5 p.i. (Fig. 3.2F-J). Notably, the Δfic::PWT-Rv3642c-
fic complementation strain restored intracellular survival to wild-type levels (Fig. 3.2G and J), 
indicating the intracellular survival deficiencies of the Δfic mutant were due to lack of fic 
expression. However, neither the ΔRv3642c::PWT-Rv3642c nor ΔRv3642c-fic::PWT-fic strains 
restored intracellular survival to wild-type H37Rv levels (Fig. 3.2G-I). The failure of 
ΔRv3642c::PWT-Rv3642c to restore intracellular survival to wild-type levels could be due to 
altered or disrupted fic expression caused by the allelic exchange of hyg
R
 with Rv3642c used to 
generate the deletion mutation.
64
 Because Rv3642c is immediately 10 bp upstream of fic (Fig. 
3.1A), the fic promoter is likely either upstream of Rv3642c or within Rv3642c, and therefore it is 
possible the exchange of hyg
R
 for Rv3642c in the ΔRv3642c::PWT-Rv3642c mutant obstructed the 
fic promoter. Nonetheless, it is notable that Rv3642c-fic expression in the Δfic::PWT-Rv3642c-fic 
strain, but not fic expression alone in the ΔRv3642c-fic::PWT-fic mutant, restored intracellular 
survival to wild-type levels (Fig. 3.2G). This result suggests that both Rv3642c and fic are 
important for intracellular survival. Altogether, the absence of fic and/or Rv3642c impairs 
intracellular survival, and intracellular survival is only recovered to wild-type levels with both fic 
and Rv3642c under native promoter control. 
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3.4 Expression and Purification of Recombinant Fic for Enzymatic Studies. 
Although Mishra et al. 2012
58
 expressed Fic with different N-terminal fusion tags, namely 
His, GST, and MBP-His, only the N-terminal MBP-His fusion yielded soluble and enzymatically 
active Fic.
58
  Therefore, to generate Fic for use in enzymatic experiments, Fic was similarly 
expressed with an N-terminal MBP-His fusion tag (MBP-Fic). Additionally, Fic was expressed with 
an N-terminal FLAG fusion tag and a C-terminal His fusion tag (FLAG-Fic). Fic motif mutants, 
whereby the histidine (H144) was changed to an alanine, were also expressed (MBP-Fic H/A and 
FLAG-Fic H/A). Recombinant proteins were purified by affinity chromatography and subsequently 
analyzed by SDS-PAGE (Fig. 3.4A-B and E-F). Although the majority of the expressed 
recombinant proteins were insoluble (data not shown), ample soluble recombinant protein (Fig. 
3.3) was expressed and purified. The expression of soluble FLAG-Fic contrasted with the very 
limited expression of N-terminal His-tagged Fic reported by Mishra et al. 2012,
58
 suggesting that a 
small C-terminal fusion tag improves Fic solubility. Concentrating MBP-Fic and FLAG-Fic with 
Amicon
TM
 concentrators resulted in complete loss of the proteins, possibly due to interactions with 
the filter membrane (data not shown). Therefore, recombinant proteins were dialyzed (Fig. 3.4C 
and G), and subsequent SYPRO ruby red staining revealed multiple non-specific E. coli proteins 
captured during purification (Fig. 3.4D and H). Previously, Fic domain protein activity was 
demonstrated directly from E. coli lysates containing the expressed Fic domain protein (without 
purification).
38
 Since highly purified Fic was not required for enzymatic assays, partially-purified 
recombinant Fic proteins (Fig. 3.3D and H) were used in enzymatic experiments. 
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Figure 3.3 Recombinant Fic Expression and Purification. (A-D) SDS-PAGE results of MBP-
Fic and MBP-Fic H/A expression and purification. Coomassie Brilliant Blue (CBB)-stained SDS-
PAGE gels showing fractions collected during Ni-NTA affinity chromatography purification of 
MBP-Fic (A) and MBP-Fic H/A (B). Purified soluble MBP-Fic and MBP-Fic H/A was dialyzed and 
stained with CBB (C) and SYPRO ruby red (SYPRO) (D). (E-H) SDS-PAGE results of FLAG-Fic 
and FLAG-Fic H/A expression and purification. CBB-stained SDS-PAGE gels showing fractions 
collected during Ni-NTA affinity chromatography purification of FLAG-Fic (E) and FLAG-Fic H/A 
(F). Purified soluble FLAG-Fic and FLAG-Fic H/A were dialyzed and stained with CBB (G) and 
SYPRO (H). Marker, protein molecular weight markers. 
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3.5 MBP-Fic and MBP-Fic H/A, but Not FLAG-Fic and FLAG-Fic H/A, Hydrolyze ATP In 
Vitro. 
In the AMPylation catalytic reaction, ATP is hydrolyzed into AMP and pyrophosphate. 
Previously, using radiolabeled α-
32
P-ATP and thin layered chromatography, Mishra et al.
58
 
showed that MBP-Fic, but not MBP-Fic H/A, hydrolyzed ATP into AMP in vitro.
58
 To determine if 
the purified recombinant Fic was enzymatically active, MBP-Fic and FLAG-Fic and their 
respective H/A mutants were tested for ATPase activity using a luciferase-based ATP 
determination assay. VopS and IbpA Fic1 were used for comparison, and MBP was used as a 
negative control. ATP was quantified from reactions incubated at 37°C for 1 h (Fig. 3.4A) and 16 
h (Fig. 3.4B). As anticipated, MBP-Fic hydrolyzed ATP (Fig. 3.4). In contrast, FLAG-Fic showed 
no difference in ATP hydrolysis compared to MBP (Fig. 3.4), suggesting that FLAG-Fic is 
catalytically inactive. Like IbpA Fic2,
43
 IbpA Fic1 exhibited ATPase activity (Fig. 3.4). Although 
VopS lacked in vitro ATPase hydrolysis activity (Fig. 3.4), it is likely that this assay lacked 
sensitivity to detect VopS ATPase activity because VopS ATPase activity is significantly greater 
with non-self substrates, i.e. Cdc42,
45
 which were not included here (Fig. 3.4). These results 
collectively suggest MBP-Fic in vitro ATPase activity is more similar to IbpA Fic1 than VopS. 
Unexpectedly, MBP-Fic H/A harbored significant ATPase activity, compared to MBP (Fig. 3.4). 
The ATPase activity of MBP-Fic H/A at 1 h was over 2-fold less than MBP-Fic when more 
enzyme (800 ng) was present in the reactions (Fig. 3.4A), but similar to MBP-Fic when less 
enzyme (400 ng) was present (Fig. 3.4B). These results demonstrated that the H/A mutation 
reduces MBP-Fic enzymatic efficiency when the enzyme is present in higher concentrations. 
Unlike MBP-Fic, IbpA Fic1 showed a decrease in ATPase activity after 1 h when higher amounts 
of enzyme were present (Fig. 3.4AB), suggesting that IbpA Fic1 activity is concentration 
dependent. Nonetheless, these MBP-Fic H/A results contradict the results obtained by Mishra et 
al.
58
 and indicate that the H/A mutation did not eliminate Fic ATPase activity. Because FLAG-Fic 
was deemed catalytically inactive (Fig. 3.4), it was not used in additional enzymatic activity 
experiments. 
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Figure 3.4 ATP Hydrolysis Activities of Recombinant Fic and Fic H/A Mutant. (A) In vitro 
ATP hydrolysis activities with 800 ng each of purified MBP, VopS, IbpA Fic1, MBP-Fic, and MBP-
Fic H/A proteins measured with a luciferase-based assay after 1 h incubation at 37ºC. Data 
shown represent the mean and standard deviation (SD) of at least three independent 
experiments with duplicate reactions. (B) In vitro ATP hydrolysis activities with 400 ng of each 
recombinant protein after incubation at 37°C for 16 h. Results represent the mean and SD from 
two replicates. All values were normalized to ATP levels for MBP (negative control) which was 
considered 100%. ** adjusted p < 0.01; **** adjusted p < 0.0001; one-way ANOVA with Dunnett’s 
post hoc test. The data used to generate these graphs were produced by our collaborators, 
Lusheng Song and Elaine Boustila. 
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3.6 MBP-Fic and MBP-Fic H/A Have Auto-AMPylation Activity. 
Many Fic domain proteins auto-AMPylate.
35,38,39,41
 MBP-Fic and MBP-Fic H/A were tested 
for auto-AMPylation using a click-chemistry in-gel fluorescence assay,
68
 using comparisons with 
VopS and IbpA Fic1 as positive controls and MBP as a negative control. In short, this assay uses 
the ATP analogue, N
6
pATP, as a cofactor for Fic domain AMPylation of protein substrate with 
N
6
pAMP, which is further cross-linked with an azide-fluorescence tag through a copper-catalyzed 
azide-alkyne reaction. AMPylated proteins were separated by SDS-PAGE, and the resulting gels 
were scanned for fluorescence, revealing fluorescently-labeled AMPylated proteins (see click 
chemistry schematic, Appendix A Fig. A). Both MBP-Fic and MBP-Fic H/A, but not MBP, 
displayed fluorescence, demonstrating auto-AMPylation activity (Fig. 3.5A). Quantification of in-
gel fluorescence revealed that MBP-Fic and MBP-Fic H/A auto-AMPylation activities were 
statistically significant compared to MBP (Fig. 3.5B). Furthermore, MBP-Fic exhibited greater 
auto-AMPylation activity than MBP-Fic H/A, corroborating the ATP hydrolysis results (Fig. 3.4). 
These results also include the first report of IbpA Fic1 auto-AMPylation, although this result was 
not unexpected as the closely related homologue IbpA Fic2 is an auto-AMPylator.
68
 
Immunodetection, with polyclonal antisera specific to either AMPylated-threonine or 
AMPylated-tyrosine residues, was used to validate the click chemistry gel assay results and to 
attempt to elucidate if the auto-AMPylation modifies a threonine or tyrosine residue. No 
discernable auto-AMPylated MBP-Fic or MBP-Fic H/A were detected (Fig. 3.5C). Moreover, there 
were no differences between IbpA Fic1 auto-AMPylation with or without ATP, and no VopS auto-
AMPylation was detected. These results altogether suggest either that all of the detected auto-
AMPylation is of serine residues or that this method (as performed) is not suitable for detecting 
auto-AMPylated Fic. Nonetheless, the click chemistry results demonstrated that Fic has auto-
AMPylation activity and that the Fic H/A mutation does not prevent Fic catalysis. 
39 
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Figure 3.5 Auto-AMPylation Activity of MBP-Fic and MBP-Fic H/A. (A) In vitro auto-
AMPylation activity of MBP-Fic, MBP-Fic H/A, IbpA Fic1, and VopS, compared to MBP (negative 
control), as shown by click chemistry in-gel fluorescence (top panels) and Coomassie brilliant 
blue staining (bottom panels). Reactions, with or without 10 mM N
6
pATP, were incubated at 30°C 
for 1 h, subjected to N
6
pAMP labeling with rhodamine dye through copper-catalyzed azide-alkyne 
cycloaddition, separated by SDS-PAGE, and scanned for fluorescence. Red arrows indicate auto-
AMPylation. Similar results were produced from at least three independent experiments. (B) 
Quantification of the click chemistry in-gel fluorescence and Coomassie brilliant blue staining 
intensities from (A). Bars above intensity threshold, represented by background fluorescence of 
MBP without ATP, indicate auto-AMPylation. (C) Immunodetection did not reveal in vitro auto-
AMPylation of threonine and tyrosine residues for VopS, IbpA Fic1, MBP-Fic, or MBP-Fic H/A, 
compared to MBP (negative control). Reactions, with or without 10 mM ATP, were incubated at 
37°C for 1 h, separated by SDS-PAGE, and subjected to western analysis, with α-AMPylated 
threonine (left panel) and α-AMPylated tyrosine antisera (center panel), or Coomassie brilliant 
blue staining (right panel). VopS- and IbpA Fic1-mediated AMPylation of GST-Rac1 threonine 
and tyrosine residues, respectively, served as positive controls for the antisera. Lanes with both 
VopS and IbpA Fic1, with or without GST-Rac1, represent separate in vitro reactions for VopS 
and IbpA Fic1 that were loaded together into the same well. Similar results were obtained from at 
least three independent experiments. CBB, Coomassie brilliant blue; a.u., average unit. Figure 
3.5A-B was produced by our collaborators, Lusheng Song and Elaine Boustila. 
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3.7 MBP-Fic and MBP-Fic H/A AMPylate THP-1 Cell Protein Substrate. 
As demonstrated in the M. tuberculosis THP-1 infection studies, fic promoted intracellular 
survival (Fig. 3.2F-J). Notably, Fic was previously detected in the culture filtrate,
61
 suggesting Fic 
is secreted and can thereby interact with macrophage proteins during infection. Therefore, it is 
plausible that Fic AMPylation of THP-1 proteins promotes intracellular survival. Through in vitro 
AMPylation assays with THP-1 proteins, using α-AMPylated-threonine and α-AMPylated tyrosine 
antisera to detect AMPylation, MBP-Fic- and MBP-Hic H/A-mediated AMPylation of a THP-1 
substrate with a molecular weight of approximately 29 kDa was detected (Fig. 3.6). Neither MBP 
nor VopS AMPylated the 29 kDa THP-1 substrate, and AMPylation reactions containing either 
only THP-1 proteins, MBP-Fic, or MBP-Fic H/A, did not produce the 29 kDa band. Further, 
AMPylation of the 29 kDa protein by MBP-Fic and MBP-Fic H/A was not prevented by heating the 
THP-1 proteins to 95°C for 5 min prior to the reaction (data not shown). Furthermore, AMPylation 
was not prevented by mixing the AMPylators and THP-1 proteins with SDS-PAGE loading dye, 
foregoing incubation at 37°C for 1 h, and immediately boiling the samples for 4 min. While pre-
heating small GTPases to 95°C for 5 min prevented AMPylation by AMPylators VopS and IbpA 
Fic1, not all proteins are irreversibly denatured under those conditions. For example, boiling VopS 
for 20 min prior to initiating the reaction did not prevent VopS AMPylation of Rac1 (data not 
shown). Likewise, SDS does not always abrogate enzymatic activity.
72
 Nonetheless, AMPylation 
of the 29 kDa substrate was only detected in reactions with 10 mM ATP and not detected in 
reactions with 1 mM ATP. Similar assays using click chemistry in-gel fluorescence with 1 mM 
N
6
pATP also did not detect AMPylation of the 29 kDa substrate (conducted by collaborators; data 
not shown). Assays using click chemistry in-gel fluorescence with 10 mM N
6
pATP have not yet 
been pursued. Altogether, Fic AMPylated a THP-1 protein substrate, suggesting that Fic 
AMPylation may have function relevant to M. tuberculosis intracellular survival.  
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Figure 3.6 AMPylation of THP-1 Cell Protein Substrate by MBP-Fic and MBP-Fic H/A. In vitro 
AMPylation reactions with or without purified VopS, MBP, MBP-Fic, and MBP-Fic H/A, and THP-1 
cell whole cell lysate (WCL). Reactions were incubated at 37°C for 1 h and subjected to western 
analysis with α-AMPylated threonine (top panel) or α-AMPylated tyrosine antisera (center panel). 
VopS AMPylation of GST-Rac1 threonine residues and IbpA Fic1 AMPylation of GST-Rac1 
tyrosine residues served as positive controls for the antisera. α-β-actin immunoblot (lower panel) 
served as a loading control. Red arrows indicate a 29 kDa protein substrate AMPylated by MBP-
Fic and MBP-Fic H/A. Similar results were obtained from at least three independent experiments. 
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3.8 MBP-Fic- and MBP-Fic H/A-Mediated AMPylation of M. tuberculosis Protein Substrate 
Was Not Detected. 
In addition to AMPylating THP-1 protein substrate, it is possible that Fic AMPylates M. 
tuberculosis proteins. Thus, MBP-Fic and MBP-Fic H/A were examined for AMPylation of M. 
tuberculosis protein targets. No Fic-mediated AMPylation of H37Rv protein substrate was 
detected using α-AMPylated threonine or α-AMPylated tyrosine antisera with either 1 mM or 10 
mm ATP (Fig. 3.7). Since the polyclonal antisera produced intense background with higher 
concentrations of H37Rv protein samples (data not shown), only 1.3 µg of total H37Rv protein, 
which is low compared to the 15 µg of total THP-1 proteins used previously, was used in the 
AMPylation assays. Click chemistry in-gel fluorescence assays with 1 mM N
6
pATP were also 
used to examine AMPylation of H37Rv WCL, but no MBP-Fic-mediated AMPylation of H37Rv 
proteins was detected (conducted by collaborators; data not shown). Although these results 
suggested that Fic does not AMPylate M. tuberculosis proteins in vitro, it is possible that the 
AMPylated target was minimally abundant and therefore below the limit of detection with the 
methods used. Therefore, it remains unclear if Fic AMPylates M. tuberculosis proteins. 
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Figure 3.7 MBP-Fic- and MBP-Fic H/A-Mediated AMPylation of M. tuberculosis Protein 
Substrate Not Detected. In vitro AMPylation reactions with or without purified VopS, MBP, MBP-
Fic, and MBP-Fic H/A, and M. tuberculosis H37Rv WCL. Reactions were incubated at 37°C for 1 
h, separated by SDS-PAGE, and subjected to western analysis, with α-AMPylated threonine (left 
panel) or α-AMPylated tyrosine antisera (center panel), or Coomassie brilliant blue (CBB) staining 
(right panel). VopS AMPylation of GST-Rac1 threonine residues and IbpA Fic1 AMPylation of 
GST-Rac1 tyrosine residues served as positive controls for the antisera. As negative controls for 
the AMPylation reaction, enzyme was mixed directly with substrate in the presence of SDS-PAGE 
loading dye, not subjected to incubation at 37°C for 1 h, and immediately boiled (no reaction). No 
bands indicating MBP-Fic- or MBP-Fic H/A-mediated AMPylation were detected. Similar results 
were obtained from at least three independent experiments.  
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3.9 Fic and Rv3642c Form a Complex with Strong Intermolecular Interactions When Co-
Expressed in E. coli. 
Fic and Rv3642c display considerable homology to Fic toxin-antitoxin systems. 
Therefore, Fic and Rv3642c were examined for toxin-antitoxin interactions. 3xFLAG-tag and 
6xHis-tag isoforms of Fic and Rv3642c were either expressed separately or co-expressed in E. 
coli, and lysates were probed with α-FLAG and α-His antibodies via western blotting (Fig. 3.8). 
Co-expressed Fic-6xHis and 3xFLAG-Rv3642c form a complex, as evident by the co-localization 
of α-FLAG and α-His bands at a molecular weight (MW) of 36 kDa, which corresponds to the 
combined molecular weight of Fic-6xHis (25 kDa) and 3xFLAG-Rv3642c (11 kDa). As expected, 
expression of 3xFLAG-Fic-6xHis yielded α-FLAG and α-His bands at 28.5 kDa. Expression of 
3xFLAG-Rv3642c-6xHis yielded α-FLAG and α-His bands that migrated at a MW slightly greater 
than the expected 12 kDa. Comparatively, expression of 3xFLAG-Rv3642c, in the co-expression 
system, yielded an α-FLAG band that migrated at a MW slightly greater than the expected 11 
kDa, but still below the 3xFLAG-Rv3642c-6xHis band. Furthermore, some non-specific bands 
were detected with expressed 3xFLAG-Fic-6xHis and 3xFLAG-Rv3642c-6xHis, which might 
represent truncated protein. Nonetheless, in the co-expression system no 25 kDa bands 
representing Fic-6xHis were detected, suggesting all of the expressed Fic-6xHis was complexed 
with 3xFLAG-Rv3642c. Interactions between 3xFLAG-Rv3642c and Fic-6xHis were notably not 
disrupted by SDS and boiling for 10 min, demonstrating robust intermolecular interactions 
between Fic and Rv3642c. These results indicated that Rv3642c and Fic form a robust complex 
comparable to Fic toxin-antitoxin systems. 
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Figure 3.8 Detection of the Rv3642c:Fic Complex When Fic and Rv3642c are Co-Expressed 
in E. coli. IPTG-induced E. coli cultures expressing 3xFLAG-Fic-6xHis (28.5 kDa), 3xFLAG-
Rv3642c-6xHis (12 kDa), or co-expressing Fic-6xHis (25 kDa) and 3xFLAG-Rv3642c (11 kDa), 
were lysed, separated by SDS-PAGE, and subjected to western analysis, with α-FLAG (left 
panel) and α-His (center panel) monoclonal antibodies, or stained with Coomassie brilliant blue 
(CBB) (right panel). The arrow indicates complexed Fic-6xHis:3xFLAG-Rv3642c (36 kDa). Similar 
results were obtained from at least three independent experiments. 
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3.10 M. tuberculosis Fic and Rv3642c Cellular Localization Studies. 
Fic was previously detected in the M. tuberculosis H37Rv culture filtrate.
61
 Conversely, 
localization of Rv3642c has yet to be reported. Additionally, Fic and Rv3642c form a complex 
when co-expressed in E. coli (Fig. 3.8), suggesting potential co-localization within M. tuberculosis. 
To determine the M. tuberculosis cellular localization of Fic and/or Rv3642c, H37Rv protein 
fractions and CFPs were probed with rabbit α-MBP-Fic and α-FLAG-Rv3642c polyclonal antisera 
(Fig. 3.9). Although no Rv3642c monomeric bands of 7.5 kDa were detected, multiple larger 
bands were detected and could represent Fic (24 kDa), multimeric Fic, or multimeric Fic:Rv3642c 
complexes (Fig. 3.9). These results suggest possible cellular localization of Fic and/or Rv3642c, 
but further experimentation is needed to validate localization. 
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Figure 3.9 Probing for Fic and Rv3642c in M. tuberculosis Protein Fractions and CFPs 
Using α-MBP-Fic and α-FLAG-Rv3642c Polyclonal Antisera. M. tuberculosis H37Rv protein 
fractions and CFPs were separated by SDS-PAGE and subjected to western analysis with α-
MBP-Fic or α-FLAG-Rv3642c polyclonal antisera. Purified MBP-Fic and FLAG-Rv3642c were 
used as positive controls. Red arrows indicate bands that might represent multimeric Fic or 
multimeric Fic-Rv3642c complexes. Marker, molecular weight markers. 
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CHAPTER 4 
DISCUSSION 
Many Fic domain proteins have important roles in bacterial pathogenesis through 
AMPylation of host proteins. We hypothesized that Fic AMPylation promotes the M. tuberculosis 
infection of macrophages. In this study, we showed that Fic promotes M. tuberculosis intracellular 
survival (Fig. 3.2). Because the Fic domain encompasses the entire Fic protein, we surmise that 
fic-mediated promotion of intracellular survival is a product of Fic AMPylation activity. Other Fic 
domain proteins have been characterized to function in promoting bacterial survival within 
macrophages. For example, AnkX is secreted by L. pneumophila during macrophage infection to 
promote bacterial survival by modifying host small GTPases.
35
 Similarly, Fic has been detected in 
the culture filtrate during M. tuberculosis in vitro growth,
61
 which suggests that Fic is a secreted 
protein. While our attempts to detect Fic in the M. tuberculosis culture filtrate are currently 
inconclusive (Fig. 3.9), we have not investigated Fic localization or secretion during macrophage 
infection. Secretion would allow Fic access to AMPylate host proteins during macrophage 
infection, which may explain how Fic promotes M. tuberculosis intracellular survival in 
macrophages. 
As M. tuberculosis Fic consists entirely of a Fic domain with robust homology to known 
AMPylators, we predicted that Fic would harbor AMPylation activity. In this study, we 
demonstrated that Fic AMPylates both itself, i.e. auto-AMPylation, and non-self proteins. The Fic 
auto-AMPylation signal was weak in comparison to IbpA Fic1 (Fig. 3.5A), and Fic auto-
AMPylation was not detected with immunodetection (Fig. 3.5C) or autoradiography (Appendix A 
Fig. B). However, Fic domain protein auto-AMPylation is poorly understood, and it is possible that 
Fic auto-AMPylation has a regulatory function. Notably, we showed that Fic AMPylates an 
unknown THP-1 protein in vitro (Fig. 3.6). Although Fic-mediated AMPylation of the THP-1 protein 
substrate was detected with immunodetection (Fig. 3.6) and not click chemistry (conducted by 
collaborators; data not shown), this discrepancy may be explained by differences in either the 
sensitivity of detection between the two methods or in the buffer compositions and ATP 
concentrations used in the two methods (Methods 2.7). Nevertheless, the THP-1 protein 
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AMPylated by Fic is approximately 29 kDa in molecular weight, which, to the best of our 
knowledge, is a different molecular weight than eukaryotic proteins previously shown to be 
AMPylated by Fic domain proteins.
35,36,39
 Although AnkX and many other Fic domain proteins of 
pathogenic bacteria target host small GTPases, we detected no Fic-mediated AMPylation of 
human small GTPases using a NAPPA protein array
42
 consisting of 22 different human GTPases 
(conducted by collaborators; data not shown). The THP-1 protein AMPylated by Fic is not likely a 
small GTPase and instead represents a novel AMPylation target of bacterial Fic domain proteins. 
Fic did not AMPylate M. tuberculosis proteins in vitro, as we detected no Fic-mediated 
AMPylation of M. tuberculosis proteins using immunodetection (Fig. 3.7), click chemistry 
(conducted by collaborators; data not shown), or auto-radiography (Appendix A Fig. B). It is, 
however, possible that M. tuberculosis protein(s) targeted by Fic were not present in our protein 
preparations or that the M. tuberculosis protein target was in too low of abundance to generate a 
detectable signal with the methods employed. Because we showed that Fic AMPylates a THP-1 
protein (Fig. 3.6) and did not AMPylate M. tuberculosis proteins (Fig. 3.7) and because there is 
evidence that Fic is secreted,
61,62
 we speculate that Fic promotes M. tuberculosis intracellular 
survival in macrophages by AMPylating host protein(s). 
Fic domain proteins in Fic toxin-antitoxin systems are characterized as bacterial toxins 
that function to inhibit bacterial growth
53,54
 and are regulated by interaction with an antitoxin.
38
 In 
this study, we also hypothesized that Fic is a toxin whose activity is regulated by its putative 
antitoxin Rv3642c. Like other Fic toxin-antitoxin systems, Fic and Rv3642c form a robust complex 
(Fig. 3.8). This complex was not disrupted by boiling or SDS, which demonstrated that Rv3642c 
has a strong affinity for Fic. Strong affinity between the toxin and antitoxin is typical of toxin-
antitoxin systems (reviewed
56
), where tight regulation of the toxin is required to prevent unwanted 
activity from the toxin.
73
 However, unlike other Fic toxin-antitoxin systems,
38,54
 Fic does not inhibit 
bacterial growth in vitro, as the presence of fic without Rv3642c did not negatively impact M. 
tuberculosis bacterial growth (Fig. 3.2C). Moreover, our results suggested that Fic and Rv3642c 
are not expressed during in vitro growth, as we did not detect Fic or Rv3642c when using 
polyclonal antisera to screen WCLs of M. tuberculosis deletion mutants, complementation strains, 
51 
 
and the H37Rv wild-type strain (data not shown). In contrast, other Fic domain proteins and 
antitoxins in Fic toxin-antitoxin systems are expressed during in vitro growth of Y. enterocolitica 
and P. aeruginosa,
53
 and seemingly in B. schoenbuchensis.
38
 Furthermore, we did not detect Fic-
mediated AMPylation of M. tuberculosis proteins that are homologous to bacterial proteins known 
to be targeted by Fic toxins (Fig. 3.7, Appendix A Fig. A), specifically GyrB and Topo IV in Y. 
enterocolitica, P. aeruginosa, and B. schoenbuchensis,
53
 and EF-Tu in E. coli.
37
 Because Fic did 
not inhibit M. tuberculosis growth in vitro (Fig. 3.2C) and did not AMPylate M. tuberculosis 
proteins (Fig. 3.7), we conclude that Fic is not toxic to M. tuberculosis during in vitro growth or 
infection of THP-1 cells. 
Interestingly, Fic-mediated promotion of M. tuberculosis intracellular survival was 
dependent on Rv3642c. Complementation with fic in the M. tuberculosis ΔRv3642c-fic mutant did 
not restore intracellular survival to wild-type levels, while complementation with Rv3642c-fic in the 
M. tuberculosis Δfic mutant restored intracellular survival to near wild-type levels (Fig. 3.2G). How 
Rv3642c supports Fic in promoting M. tuberculosis intracellular survival is unknown, but because 
Fic may require intermolecular interaction for activity, it is possible that Rv3642c functions to 
stabilize Fic activity. While recombinant Fic was catalytically active with the large MBP N-terminal 
fusion tag, Fic was not active with the smaller 3xFLAG (Fig. 3.4), 6xHis (Fig. 3.4), or GST fusion 
tags,
58
 which suggests that Fic activity may require intermolecular interactions, which are 
artificially provided in vitro by the MBP tag. 
The histidine of the Fic domain catalytic loop is universally thought to be critical for 
AMPylation activity, (reviewed
31
) as its predicted role in AMPylation is to deprotonate the hydroxyl 
group of the protein substrate threonine, serine, or tyrosine residue,
45
 thus prepping that residue 
to perform nucleophilic attack on the cofactor, i.e. ATP.
43
 However, we found that mutation of the 
catalytic loop histidine of Fic had little to no effect on the ability of Fic to hydrolyze ATP (Fig. 3.4), 
auto-AMPylate (Fig. 3.5), or AMPylate the THP-1 protein substrate (Fig. 3.6). These results 
contradicted previous research which showed that M. tuberculosis Fic H/A is unable to hydrolyze 
ATP into AMP.
58
 The discrepancy between our results and those of Mishra et al.
58
 can possibly 
be explained by differences in sensitivity among the techniques used. Regardless, our results  
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clearly showed that Fic H/A is catalytically active (Fig. 3.4, Fig. 3.5A-B, Fig. 3.6). Similarly, the H. 
somni IbpA Fic2 H/A mutant retained activity, albeit at reduced levels.
34
 It is unknown how Fic 
efficiently catalyzes AMPylation with the H/A mutation, and uncovering the mechanism may 
challenge the dogma that the Fic domain histidine residue is universally critical for Fic enzymatic 
activity. 
In summary, we identified an AMPylator that functions to promote M. tuberculosis 
intracellular survival in macrophages, most likely by AMPylation of a host protein. According to 
our findings, Fic and Rv3642c represents the first Fic toxin-antitoxin-like system that does not 
function to regulate bacterial growth. We also provide novel evidence of a Fic toxin-antitoxin-like 
system that functions to promote intracellular bacterial survival by targeting host proteins. 
Importantly, this research underscores the potential importance of Fic in tuberculosis 
pathogenesis. Because the infection of macrophages is a critical virulence strategy in 
tuberculosis pathogenesis, weakening M. tuberculosis macrophage infection by inhibiting Fic 
might be a viable therapeutic strategy. Indeed, small molecular inhibitors have previously been 
demonstrated to inhibit the activity of Fic domain proteins,
74
 demonstrating that Fic domain 
proteins can be targeted for inhibition. Because Rv3642c is required for Fic-mediated intracellular 
survival, Rv3642c may also serve as a drug target. 
These research studies prompt mechanistic investigations to determine how Fic 
influences M. tuberculosis intracellular survival in macrophages. Identifying the THP-1 protein 
AMPylated by M. tuberculosis Fic would provide critical insight into potential effects on 
intracellular survival. Given that Fic function is linked to Rv3642c, it will also be pertinent to 
understand how Rv3642c supports Fic in promoting M. tuberculosis intracellular survival. If 
Rv3642c stabilizes Fic activity, then antitoxins may have additional functionality as “protoxins”. 
Nonetheless, in addition to macrophages, M. tuberculosis infects monocytes, dendritic cells, and 
neutrophils. It is therefore entirely possible that Fic also supports intracellular infection of cell 
types other than macrophages. Additionally, determining the function of Fic auto-AMPylation and 
how Fic catalyzes AMPylation without the Fic motif histidine will further advance our 
53 
 
understanding of Fic proteins. Collectively, future experiments to test these possibilities will 
provide more insight to Fic domain proteins and tuberculosis pathogenesis.  
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APPENDIX A 
ADDITIONAL FIGURES AND TABLES 
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Figure A. Schematic of Click Chemistry AMPylation Reaction. In the click chemistry reaction 
for AMPylation detection, the ATP analogue N
6
-propargyl adenosine-5'-triphosphate (N
6
pATP) is 
first used by AMPylators to modify substrate with N
6
pAMP. Then, through Cu(I)-catalyzed azide-
alkyne cycloaddition, the N
6
pAMP is labeled with an azide-rhodamine fluorescent dye. 
AMPylation is then analyzed by mass spectrometry or via SDS-PAGE and subsequent in-gel 
fluorescence scanning. Adapted from Grammel et al., 2011.
68
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Figure B. In vitro AMPylation Assays Using α-
32
P-ATP. Screening of MBP-Fic- and MBP-Fic 
H/A-mediated AMPylation of M. tuberculosis and HeLa cell protein substrate using α-
32
P-ATP. In 
vitro AMPylation reactions with or without purified 230ng VopS, 3µg MBP-Fic, 3µg MBP-Fic H/A, 
with or without 10µg HeLa whole cell lysate (WCL) or 10µg M. tuberculosis H37Rv WCL, and 
1mM cold ATP or 10µCi α-
32
P-ATP (3,000 Ci/mmol), were incubated at 30°C or 37°C for 1 h. 
Reactions were separated by SDS-PAGE and gels with cold ATP were stained with Coomassie 
brilliant blue (CBB), and gels with hot ATP were visualized using a phosphorimager (top panels). 
VopS AMPylation of endogenous Rac1 in HeLa lysate served as a positive control. MBP-Fic and 
MBP-Fic H/A produced an auto-radiography band of approximately 45 kDa in molecular weight 
(MW) in HeLa WCL. This band was not present in HeLa WCL by itself or with VopS, and 
therefore might represent an AMPylated substrate. Furthermore, an auto-radiography band of 
about 52 kDa in MW was present in HeLa WCL by itself and with VopS, but absent with MBP-Fic 
and MBP-Fic H/A,  and might represent a loss of endogenous HeLa cell AMPylation. Note that an 
MBP control was not used in this experiment, thus MBP cannot be ruled out as the cause of 
these bands. Heat-denaturing of MBP-Fic, by heating at 95°C for 5 min, had no apparent effect 
on enzymatic activity. No bands were generated with H37Rv WCL. Reactions incubated at 37°C 
were as described in materials and methods, and reactions incubated at 30°C were at 1/5 
reagent strength. These images are representative of a single experiment. H144A, H/A mutation.  
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Table 1. 
M. tuberculosis Strains Used in this Study. 
Strain   Description 
H37Rv   Wild-type 
STS80   ΔRv3642c-fic::Hyg
R
 
STS81   ΔRv3642c::Hyg
R
 
STS82   Δfic::Hyg
R
 
STS83   ΔRv3642c-fic::Hyg
R
, ectopic PWT-fic at attBL5 
STS86   ΔRv3642c::Hyg
R
, ectopic PWT-Rv3642c at attBL5 
STS91   Δfic::Hyg
R
, ectopic PWT-Rv3642c-fic at attBL5 
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Table 2. 
DNA Primers Used in this Study. 
Primers  Sequence      Use 
SH418  5’-GAGGTACCAAAGCCGCCTTAGCTCAGTC-3’  Cloning fic 5’ flanking arm, F 
SH419  5’-GATCTAGAGCACTCCACCCCGGTTACTG-3’  Cloning fic 5’ flanking arm, R 
SH420  5’-CCCAAGCTTCTGATCGCACTAACCTCCTG-3’  Cloning fic 3’ flanking arm, F 
SH421  5’-CCGACTATGCGCTTCAACGCCTTCACCAG-3’  Cloning fic 3’ flanking arm, R 
SH422  5’-AAGGTACCATCGATCTGGCGACCTACTTC-3’  Cloning Rv3642c 5’ flanking arm, F 
SH423  5’-GCTCTAGACACTTCATCTCATTTGGTGG-3’  Cloning Rv3642c 5’ flanking arm, R 
SH424  5’-CCCAAGCTTACATCCAGTAACCGGGGTGG-3’  Cloning Rv3642c 3’ flanking arm, F 
SH425  5’-CCGACTATGGCCGATCCGTTCAGTGGCTT-3’  Cloning Rv3642c 3’ flanking arm, R 
SH428  5’-AAGGTACCAGCCCTATCGAGCGTTCCAC-3’  Cloning Rv3642c, and Rv3642c-fic 
        complementation, F 
SH429  5’-CCTCTAGAATGCCGACTGTCCGCAGATC-3’  Cloning Rv3642c complementation, R 
SH430  5’-CCTCTAGAAGTCGACGCCATCACCAGTG-3’  Cloning fic, and Rv3642c-fic 
complementation, R 
SH435  5’-CAACTCGGCTGCTTCATCTCATTTGGTGGTCC-3’  Cloning fic complementation, FM 
SH436  5’-AAATGAGATGAAGCAGCCGAGTTGGGTGAGCGC-3’ Cloning fic complementation, RM 
SH467  5’-ACCGTATTACCGCCTTTGAGTGAG-3’   Sequencing pSH492 MCS, F 
SH468  5’-TTCGCCCTGTCGTTCACGGCTCTAG-3’   Sequencing pSH492 MCS, R 
SH437  5’-TAAGCTAGCCCGCATCCATGGGACACCGG-3’  Cloning fic into pTZ842, F 
SH438  5’-AGAGCTCGAGGAAGTCGTAAGTGGGCTCGG-3’  Cloning fic, and Rv3642c-fic into pTZ842, R 
SH439  5’-ATCGCTAGCTTTGTCCAGGCGACCGAGTTG-3’  Cloning Rv3642c, and Rv3642c-fic into 
pTZ842, F 
SH440  5’-TATACTCGAGCTGGATGTTGTACCGGCGGCG-3’  Cloning Rv3642c into pTZ842, R 
SH523  5’-TACTTCCAATCCAATGTGCCGCATCCATGGGAC-3’  Cloning fic, and fic H144A into pMCSG19, F 
SH524  5’-TTATCCACTTCCAATGTCAGAAGTCGTAAGTGGGC-3’ Cloning fic, and fic H144A into pMCSG19, R 
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Table 3. 
Plasmids, Phasmids, and Phages Used in this Study. 
Plasmid or phasmid/phage   Description 
pYUB854    res-hyg
R
-res, cosλ, oriE
64
 
pSH842     pYUB854 derivative, 5’ and 3’ fic flanking arms 
pSH847     pYUB854 derivative, 5’ and 3’ Rv3642c flanking arms 
pSH852     pYUB854 derivative, 5’ and 3’ Rv3642c-fic flanking arms 
phAE87     Conditionally replicating shuttle phasmid
64
 
phSH842     phAE87::pSH842 
phSH847     phAE87::pSH847 
phSH852     phAE87::pSH852 
pMV306     Km
R
, ColE1 origin, intL5, attPL5, integrates at attBL5 site
75
 
pSH492     pMV306 derivative, Am
R
 
pSH844     pSH492::Rv3642c complementation 
pSH872     pSH492::fic complementation 
pSH874     pSH492::Rv3642c-fic complementation 
pTZ842     pET24(b) derivative, N-terminal 3xFLAG and C-terminal 6xHis at MCS
67
 
pSH854     pTZ842 derivative, FLAG-Fic expression 
pSH855     pTZ842 derivative, 3xFLAG-Rv3642c-6xHis expression 
pSH856     pTZ842 derivative, 3xFLAG-Rv3642c and Fic-6xHis co-expression 
pSH861     pTZ842 derivative, FLAG-Fic H144A expression 
pET-GSTx::Δ30 VopS    GST-Δ30 VopS expression
68
 
pET-GSTx::IbpA Fic1    GST-IbpA Fic1 expression
34
  
pET-GSTx::Rac1 G12V   GST-Rac1 G12V expression
34
 
pMCSG19     N-terminal MBP-6xHis at MCS, MBP expression
58
 
pSH900     pMCSG19 derivative, MBP-Fic expression 
pSH901     pMCSG19 derivative, MBP-Fic H144A expression 
pcDNA6.2/N-EmGFP-DEST::fic   template plasmid for fic H144A PCR amplification 
